A STING-related prognostic score predicts high-risk patients of colorectal cancer and provides insights into immunotherapy

Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.

Download Full-text

The Use of an Algorithm for Prophylactic Mesh Use in High Risk Patients Reduces the Incidence of Incisional Hernia Following Laparotomy for Colorectal Cancer Resection

Cirugía Española (English Edition) ◽

10.1016/j.cireng.2017.03.016 ◽

2017 ◽

Vol 95 (4) ◽

pp. 222-228 ◽

Cited By ~ 2

Author(s):

Núria Argudo ◽

M. Pilar Iskra ◽

Miguel Pera ◽

Juan J. Sancho ◽

Luis Grande ◽

...

Keyword(s):

Colorectal Cancer ◽

High Risk ◽

Incisional Hernia ◽

Prophylactic Mesh ◽

Cancer Resection ◽

High Risk Patients ◽

Colorectal Cancer Resection ◽

Risk Patients

Download Full-text

G-CSF PROPHYLAXIS IN HIGH RISK PATIENTS WITH COLORECTAL CANCER

Shock ◽

10.1097/00024382-200206001-00107 ◽

2002 ◽

Vol 17 (Supplement) ◽

pp. 36

Author(s):

A. Torossian ◽

A. Bauhofer ◽

M. Middeke ◽

U. Plaul ◽

H. Wulf ◽

...

Keyword(s):

Colorectal Cancer ◽

High Risk ◽

High Risk Patients ◽

Risk Patients

Download Full-text

Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer

PLoS ONE ◽

10.1371/journal.pone.0252897 ◽

2021 ◽

Vol 16 (6) ◽

pp. e0252897

Author(s):

Thaer S. A. Abdalla ◽

Jan Meiners ◽

Sabine Riethdorf ◽

Alexandra König ◽

Nathaniel Melling ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

High Risk ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Stage I ◽

Clinicopathological Parameters ◽

Curative Intent ◽

High Risk Patients ◽

Risk Patients

Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. There is an urgent need to identify prognostic markers for patients undergoing curative resection of CRC. The detection of circulating tumor cells in peripheral blood is a promising approach to identify high-risk patients with disseminated disease in colorectal cancer. This study aims to evaluate the prognostic relevance of preoperative CTCs using the Cellsearch® system (CS) in patients, who underwent resection with curative intent of different stages (UICC I-IV) of colorectal cancer. Out of 91 Patients who underwent colorectal resection, 68 patients were included in this study. CTC analysis was performed in patients with CRC UICC stages I-IV immediately before surgery. Data were correlated with clinicopathological parameters and patient outcomes. One or more CTCs/7.5 mL were detected in 45.6% (31/68) of patients. CTCs were detected in all stages of the Union of International Cancer Control (UICC), in stage I (1/4, 25%), in stage II (4/12, 33.3%), in stage III (5/19, 26.3%) and in stage IV (21/33, 63.6%). The detection of ≥ 1 CTCs/ 7.5ml correlated to the presence of distant overt metastases (p = 0.014) as well as with shorter progression-free (p = 0.008) and overall survival (p = 0.008). Multivariate analyses showed that the detection of ≥ 1 CTCs/ 7.5ml is an independent prognostic indicator for overall survival (HR, 3.14; 95% CI, 1.18–8.32; p = 0.021). The detection of CTCs is an independent and strong prognostic factor in CRC, which might improve the identification of high-risk patients in future clinical trials.

Download Full-text

Author Correction: Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials

Current Colorectal Cancer Reports ◽

10.1007/s11888-017-0392-3 ◽

2017 ◽

Vol 13 (6) ◽

pp. 489-491

Author(s):

Dora Colussi ◽

Franco Bazzoli ◽

Luigi Ricciardiello

Keyword(s):

Colorectal Cancer ◽

Clinical Trials ◽

High Risk ◽

Molecular Targets ◽

High Risk Patients ◽

Risk Patients

Download Full-text

External validation of the Glasgow prognostic score (mGPS) for renal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.5_suppl.378 ◽

2012 ◽

Vol 30 (5_suppl) ◽

pp. 378-378

Author(s):

Viraj A. Master ◽

Timothy V. Johnson ◽

Omer Kucuk ◽

Daniel Canter ◽

John Pattaras ◽

...

Keyword(s):

High Risk ◽

Cox Regression ◽

Inflammatory Responses ◽

Prognostic Score ◽

External Validation ◽

Glasgow Prognostic Score ◽

Low Risk ◽

High Risk Patients ◽

Increased Risk ◽

Risk Patients

378 Background: Inflammation has been termed the 7th hallmark of cancer (Hanahan and Weinberg Cell 2011). Measurement of systemic inflammatory responses in malignancy is possible using a selective combination of two commonly available, cost-effective serum assays. The combination of these two serum markers, C-reactive protein (CRP) and albumin, is termed the modified Glasgow prognostic score (mGPS), and is strongly correlated with outcome in a variety of cancers, including mRCC. Recently, mGPS has been shown to be predictive of outcome in localized RCC (ASCO GU 2010 #390). We sought to externally validate these results. Methods: Nephrectomized patients with clinically localized (T1-T4N0M0) clear cell RCC with negative surgical margins were followed for a mean of 25 months (range: 1-81 months). Relapse and survival was identified through routine follow-up. Patients were categorized by mGPS score as Low Risk (mGPS = 0 points), Intermediate Risk (mGPS = 1 point), and High Risk (mGPS = 2 points). One point was assigned to patients for an elevated CRP (>10 mg/L) and hypoalbuminemia (<3.5 mg/dL). Patients with normal CRP and hypoalbuminemia were assigned 0 points. Kaplan-Meier and multivariate Cox regression analyses examined relapse-free survival (RFS) and overall survival (OS) across patient and disease characteristics. Results: Of 248 patients, 17.9% relapsed and 18.6% died. Of Low, Intermediate, and High Risk patients, 7.2%, 7.7%, and 45.5%, respectively relapsed and 5.2%, 15.4%, and 39.4%, respectively died during the study. In multivariate analysis including stage and grade, mGPS was significantly associated with RFS and OS. Compared to Low-Risk patients, High-Risk patients experienced a 3-fold (OR: 2.906, 95% CI: 1.055-8.001) increased risk of relapse and 4-fold (HR: 3.722, 95% CI: 1.046-13.245) increased risk of mortality. AUC is 0.813, which compares very favorably to existing prognostic algorithms. Conclusions: In this external validation cohort of US patients, mGPS continues to be a predictor of relapse and overall mortality following nephrectomy for localized RCC. Clinicians may consider using mGPS as an adjunct to identify high-risk patients for possible enrollment into clinical trials, or for patient counseling.

Download Full-text